Do analysts prefer ZYBT or ZNTL?

Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 117.04%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zentalis Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has better earnings and valuation, ZYBT or ZNTL?

Zhengye Biotechnology has higher earnings, but lower revenue than Zentalis Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A Zentalis Pharmaceuticals $67.43M 3.31 -$137.06M -$1.95 N/A

Is ZYBT or ZNTL more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Zentalis Pharmaceuticals N/A -70.18% -51.46%

Do analysts prefer ZYBT or CRDL?

Cardiol Therapeutics has a consensus price target of $10.00, indicating a potential upside of 433.33%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardiol Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has higher valuation and earnings, ZYBT or CRDL?

Zhengye Biotechnology has higher revenue and earnings than Cardiol Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A Cardiol Therapeutics N/A N/A -$24.20M -$0.25 N/A

Is ZYBT or CRDL more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Cardiol Therapeutics N/A -180.44% -140.28%

Do analysts rate ACB or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.50 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, ACB or ZYBT?

Zhengye Biotechnology has lower revenue, but higher earnings than Aurora Cannabis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aurora Cannabis $247.82M 1.01 -$88.13M -$1.41 N/A Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A

Which has higher earnings and valuation, NMRA or ZYBT?

Zhengye Biotechnology has higher revenue and earnings than Neumora Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Neumora Therapeutics N/A N/A -$236.93M -$1.23 N/A Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A

Is NMRA or ZYBT more profitable?

Zhengye Biotechnology's return on equity of 0.00% beat Neumora Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neumora Therapeutics N/A -242.28% -131.32% Zhengye Biotechnology N/A N/A N/A

Do analysts prefer SIGA or ZYBT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, SIGA or ZYBT?

Siga Technologies has higher revenue and earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Siga Technologies $94.57M 2.39 $23.28M -$0.05 N/A Zhengye Biotechnology $16.64M 3.90 -$9.98M N/A N/A

Zhengye Biotechnology (ZYBT) Competitors

$1.37 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.32 -0.05 (-3.28%)

As of 09/18/2026 07:56 PM Eastern

Compare

ZYBT vs. ZNTL, CRDL, ACB, NMRA, and SIGA

Should you buy Zhengye Biotechnology stock or one of its competitors? Zhengye Biotechnology's main competitors and comparable companies include Zentalis Pharmaceuticals (ZNTL), Cardiol Therapeutics (CRDL), Aurora Cannabis (ACB), Neumora Therapeutics (NMRA), and Siga Technologies (SIGA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Zhengye Biotechnology (NASDAQ:ZYBT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Zentalis Pharmaceuticals had 4 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 4 mentions for Zentalis Pharmaceuticals and 0 mentions for Zhengye Biotechnology. Zentalis Pharmaceuticals' average media sentiment score of 0.17 beat Zhengye Biotechnology's score of 0.00 indicating that Zentalis Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Zentalis Pharmaceuticals	Neutral

Zentalis Pharmaceuticals has a consensus target price of $6.75, indicating a potential upside of 117.04%. Given Zentalis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Zentalis Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zentalis Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.40

Zhengye Biotechnology has a beta of -2.56, meaning that its share price is 356% less volatile than the broader market. Comparatively, Zentalis Pharmaceuticals has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Zhengye Biotechnology has higher earnings, but lower revenue than Zentalis Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A
Zentalis Pharmaceuticals	$67.43M	3.31	-$137.06M	-$1.95	N/A

Zhengye Biotechnology's return on equity of 0.00% beat Zentalis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Zentalis Pharmaceuticals	N/A	-70.18%	-51.46%

Summary

Zentalis Pharmaceuticals beats Zhengye Biotechnology on 7 of the 11 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Zhengye Biotechnology (NASDAQ:ZYBT) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Cardiol Therapeutics has a consensus price target of $10.00, indicating a potential upside of 433.33%. Given Cardiol Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Cardiol Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

12.5% of Cardiol Therapeutics shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Zhengye Biotechnology has higher revenue and earnings than Cardiol Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

Zhengye Biotechnology has a beta of -2.56, indicating that its stock price is 356% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the broader market.

In the previous week, Cardiol Therapeutics had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Cardiol Therapeutics and 0 mentions for Zhengye Biotechnology. Cardiol Therapeutics' average media sentiment score of 0.44 beat Zhengye Biotechnology's score of 0.00 indicating that Cardiol Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Cardiol Therapeutics	Neutral

Zhengye Biotechnology's return on equity of 0.00% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Summary

Cardiol Therapeutics beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Aurora Cannabis?

Aurora Cannabis (NASDAQ:ACB) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Aurora Cannabis has a beta of 0.63, meaning that its stock price is 37% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, meaning that its stock price is 356% less volatile than the broader market.

47.6% of Aurora Cannabis shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology has lower revenue, but higher earnings than Aurora Cannabis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurora Cannabis	$247.82M	1.01	-$88.13M	-$1.41	N/A
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A

In the previous week, Aurora Cannabis had 7 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 7 mentions for Aurora Cannabis and 0 mentions for Zhengye Biotechnology. Aurora Cannabis' average media sentiment score of 0.18 beat Zhengye Biotechnology's score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the media.

Company	Overall Sentiment
Aurora Cannabis	Neutral
Zhengye Biotechnology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurora Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Zhengye Biotechnology has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Zhengye Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurora Cannabis	-32.26%	4.37%	3.45%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Aurora Cannabis beats Zhengye Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Neumora Therapeutics (NASDAQ:NMRA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Zhengye Biotechnology's return on equity of 0.00% beat Neumora Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neumora Therapeutics	N/A	-242.28%	-131.32%
Zhengye Biotechnology	N/A	N/A	N/A

Neumora Therapeutics has a beta of 2.71, meaning that its share price is 171% more volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, meaning that its share price is 356% less volatile than the broader market.

Neumora Therapeutics currently has a consensus price target of $6.57, suggesting a potential upside of 800.20%. Given Neumora Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Neumora Therapeutics is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neumora Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

47.7% of Neumora Therapeutics shares are owned by institutional investors. 26.9% of Neumora Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Zhengye Biotechnology has higher revenue and earnings than Neumora Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neumora Therapeutics	N/A	N/A	-$236.93M	-$1.23	N/A
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A

In the previous week, Neumora Therapeutics had 2 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Zhengye Biotechnology. Neumora Therapeutics' average media sentiment score of 0.45 beat Zhengye Biotechnology's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Neumora Therapeutics	Neutral
Zhengye Biotechnology	Neutral

Summary

Neumora Therapeutics beats Zhengye Biotechnology on 9 of the 13 factors compared between the two stocks.

How does Zhengye Biotechnology compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment.

Siga Technologies has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.56, indicating that its share price is 356% less volatile than the broader market.

55.4% of Siga Technologies shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Siga Technologies has higher revenue and earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	2.39	$23.28M	-$0.05	N/A
Zhengye Biotechnology	$16.64M	3.90	-$9.98M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Siga Technologies' average media sentiment score of 0.00 equaled Zhengye Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Siga Technologies	Neutral
Zhengye Biotechnology	Neutral

Zhengye Biotechnology has a net margin of 0.00% compared to Siga Technologies' net margin of -5.19%. Zhengye Biotechnology's return on equity of 0.00% beat Siga Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	-5.19%	-1.55%	-1.32%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Siga Technologies beats Zhengye Biotechnology on 5 of the 9 factors compared between the two stocks.

Get Zhengye Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZYBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZYBT vs. The Competition

Export

Metric	Zhengye Biotechnology	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$64.93M	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	N/A	792.21	274.93	25.38
Price / Sales	3.90	753.62	646.01	89.45
Price / Cash	N/A	86.36	76.25	51.42
Price / Book	1.47	10.53	10.46	6.33
Net Income	-$9.98M	$2.82B	$3.49B	$358.33M
7 Day Performance	-11.61%	1.69%	0.59%	1.12%
1 Month Performance	-27.51%	0.24%	-1.74%	-2.39%
1 Year Performance	-85.16%	3.95%	18.13%	5.35%

Zhengye Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZYBT Zhengye Biotechnology	0.422 of 5 stars	$1.37 flat	N/A	-85.2%	$64.93M	$16.64M	N/A	269
ZNTL Zentalis Pharmaceuticals	3.5052 of 5 stars	$3.59 -5.5%	$6.75 +88.0%	+104.6%	$272.35M	$67.43M	N/A	160	Positive News Analyst Forecast
CRDL Cardiol Therapeutics	2.656 of 5 stars	$1.98 -13.5%	$10.00 +405.1%	+67.4%	$265.47M	N/A	N/A	20	News Coverage
ACB Aurora Cannabis	1.0864 of 5 stars	$3.73 -3.9%	N/A	-24.0%	$251.59M	$247.82M	N/A	1,028	Analyst Downgrade
NMRA Neumora Therapeutics	1.8027 of 5 stars	$1.14 -5.0%	$6.57 +476.4%	-58.5%	$225.48M	N/A	N/A	108	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZYBT) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ZNTL, CRDL, ACB, NMRA, and SIGA

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Summary

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Summary

How does Zhengye Biotechnology compare to Aurora Cannabis?

Summary

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Summary

How does Zhengye Biotechnology compare to Siga Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Zhengye Biotechnology (ZYBT) Competitors

ZYBT vs. ZNTL, CRDL, ACB, NMRA, and SIGA

How does Zhengye Biotechnology compare to Zentalis Pharmaceuticals?

Does the media refer more to ZYBT or ZNTL?

Do analysts prefer ZYBT or ZNTL?

Which has more volatility and risk, ZYBT or ZNTL?

Which has better earnings and valuation, ZYBT or ZNTL?

Is ZYBT or ZNTL more profitable?

Summary

How does Zhengye Biotechnology compare to Cardiol Therapeutics?

Do analysts prefer ZYBT or CRDL?

Do institutionals & insiders believe in ZYBT or CRDL?

Which has higher valuation and earnings, ZYBT or CRDL?

Which has more volatility & risk, ZYBT or CRDL?

Does the media prefer ZYBT or CRDL?

Is ZYBT or CRDL more profitable?

Summary

How does Zhengye Biotechnology compare to Aurora Cannabis?

Which has more risk & volatility, ACB or ZYBT?

Do insiders & institutionals believe in ACB or ZYBT?

Which has stronger earnings and valuation, ACB or ZYBT?

Does the media favor ACB or ZYBT?

Do analysts rate ACB or ZYBT?

Is ACB or ZYBT more profitable?

Summary

How does Zhengye Biotechnology compare to Neumora Therapeutics?

Is NMRA or ZYBT more profitable?

Which has more risk and volatility, NMRA or ZYBT?

Do analysts recommend NMRA or ZYBT?

Do insiders and institutionals hold more shares of NMRA or ZYBT?

Which has higher earnings and valuation, NMRA or ZYBT?

Does the media refer more to NMRA or ZYBT?

Summary

How does Zhengye Biotechnology compare to Siga Technologies?

Which has more risk and volatility, SIGA or ZYBT?

Do institutionals and insiders believe in SIGA or ZYBT?

Which has higher valuation and earnings, SIGA or ZYBT?

Do analysts prefer SIGA or ZYBT?

Does the media favor SIGA or ZYBT?

Is SIGA or ZYBT more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZYBT vs. The Competition

Zhengye Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools